

amino acid substitutions indicated in the constrained helical peptides series I to XII as shown in Figures 23A to 23D. In other embodiments, the compound is selected from the group consisting of constrained helical peptides of each possible sequence having any one or any combination of amino acid truncations indicated in the constrained helical peptide series I to XII as shown in Figures 23A to 23D. In yet other embodiments, the compound is selected from the group consisting of constrained helical peptides of each possible sequence having any one or any combination of amino acid substitutions indicated in the constrained helical peptide series I to XII as shown in Figures 23A to 23D in combination with any one or any combination of amino acid truncations indicated in the constrained helical peptide series I to XII as shown in Figures 23A to 23D. The "X" in these sequences can be any non helix-breaking amino acid.--

#### **REMARKS**

Applicants submit this Preliminary Amendment to correct the Specification as indicated so that the descriptions therein of the figures numerically match the substitute drawings submitted in response to the Notice to File Corrected Application Papers. Applicants respectfully submit that no new matter has been added in either the drawings or the Specification.

In view of the above, Applicants submit that this application is in condition for examination on the merits and favorable consideration is respectfully requested. Early notification of such action is earnestly solicited. Should the Examiner have any suggestions to

place the application in even better condition for allowance, Applicants request that the Examiner contact the undersigned representative at the telephone number below.

Respectfully submitted,

PIPER MARBURY RUDNICK & WOLFE LLP

12-20-0001

Date

Laura D. Nammo

Steven B. Kelber

Registration No.: 30,078

Attorney of Record

Laura D. Nammo

Registration No.: 42,024

1200 Nineteenth Street, N.W.  
Washington, D.C. 20036-2412  
Telephone: (202) 861-3900  
Facsimile : (202) 223-2085

SERIAL NO. 09/854,816

DOCKET NO.: 9491-053-27 DIV

**MARKED-UP PARAGRAPHS, AS AMENDED**

**Replacement for the fifth paragraph on page 8, lines 13-22:**

--Figures 16A to [16G] 16M present amino acid sequences of gp41 from known HIV virus strains and their consensus sequences based on statistical amino acid frequency. Amino acids are represented by the standard single letter code. The strains within each HIV clade are presented. A “-” in a sequence represents the amino acid present in the consensus sequence for that clade. A “.” represents an amino acid gap. A “?” in a consensus sequence represents any amino acid at that corresponding position found in a viral sequence within that clade. A lower case amino acid represents the most frequent amino acid from among all amino acids at that corresponding position in viral sequences within that clade. An upper case amino acid in a consensus sequence indicates that only that amino acid is found at that corresponding position in viral sequences within that clade. Strain designations with no sequence information indicate that the complete gp41 sequence has not been determined.--

**Replacement for the fifth paragraph on page 9, lines 18-35:**

--[Figure 23 presents] Figures 23A to 23D present a shorthand notation of specific peptides in peptide series I through XII (as in Figure 18), indicating locking positions, amino acid substitution variant peptides, and truncation variant peptides of each. The “X” indicates a position that can be substituted with any non helix-breaking amino acid, but preferably with an amino acid present in that position from any one of the known HIV sequences shown in Figure 16. The “B” indicates a position used for the bridging (or tethering or locking) residues.

Preferred **f** positions are presented for locking; however, in less preferred embodiments the **c** and some **b** positions can be used for locking. As in Figure 18, locations of internal sequences relevant to the invention are those found between locking residues whose positions are indicated by the “|” symbols and correspond to assigned position **f**, in this example. Positions for placing either one, two or three locks in the representative presented sequences are shown. The figure delineates five **gabcde** form helical sections suitable for locking when locks occur at adjacent **f** positions. The “.” indicates positions that can be optionally absent from the final constrained helical peptide compound without substantially effecting the helical properties and groove binding properties of the final constrained helical peptide. For example, a peptide based on peptide I, having the three locks placed as indicated, can optionally lack any one or all of the five N-terminal amino acids WXXWE, which are marked by a “.”. Further, another series of truncated variants is indicated in the figure--C-terminal truncated variants--since the five C-terminal residues (LWNWF) [are] marked with a “.” can be absent. When the lock is placed more centrally in the 633-678 sequence, as shown in peptide series II, peptides in this series can lack additional amino acids at the C-terminal end as indicated by the “.” marked positions.--

**Replacement for the second full paragraph on page 77, lines 5-14:**

--The peptides of the invention may further include homolog sequences of the HIV LAI strain 633-678 sequence which exhibit antiviral activity when in constrained helical form. Most preferably, the constrained peptides, when used as haptens, will generate antibodies that block viral fusion events, leading to an inhibition of viral infectivity. Such homologs are peptides whose amino acid sequences are comprised of the amino acid sequences of peptide regions of other (i.e., other than HIV-1LAI) viruses that correspond to the gp41 peptide region of 633-678.

Such viruses may include, but are not limited to, other HIV-1 isolates and HIV-2 isolates.

Homologs derived from the corresponding gp41 peptide region of other (i.e., non HIV-1LAI)

HIV-1 isolates may include those [provide] provided in Figures 16A to [16G] 16M, or other

known corresponding sequences. Particularly preferred are those derived from HIV-1SF2, HIV-1RF, and HIV-1MN, GNE6, GNE8, and Thai strain isolate A244.--

**Replacement for the third full paragraph on page 77, lines 15-17:**

In a particularly preferred embodiment, amino acids at positions **a** and **d** of the internal sequence of six amino acids are not amino acid substituted in the helical peptide, but are the amino acids in the known isolates or consensus sequences (see Figures [16A-16G] 16A-16M and 17).--

**Replacement for the fifth full paragraph beginning on page 77, line 31 and ending on page 78, line 9:**

--Preferred compounds of the invention can include sequences from HIV-1 clade consensus sequences:

(clade B consensus) W m e W e r E I d n Y T ? I I y t L I e e s Q n Q Q e k N e q e L L e L d k W a s L w n W f (SEQ ID NO: 109);

(clade A consensus) W L q W d K E I s n Y T ? I I Y n L I E e S q n Q Q E k N E q d L L A L D K W a n L w n W F (SEQ ID NO: 110);

(clade C consensus) W M q W D R E I S N Y T d t I Y r L L E D S Q N Q Q E r N E K D L L A L D S W k N L W N W F (SEQ ID NO: 111);

(clade D consensus) W m e W E r E I d N Y T G I I Y s L I E e S Q I Q Q E K N E k e L L e L D K W A S L W N W F (SEQ ID NO: 112); and

(clade E consensus) W I E W e R E I S N Y T N q I Y e I L T e S Q n Q Q D R N E K D L L e L  
D K W A S L W n W f (SEQ ID NO: 113).

The amino acids in these sequences are represented by a single letter code, wherein a lower case letter is the represented amino acid or is substituted with an amino acid from that corresponding position in a sequence within the same clade, and wherein a ? is any amino acid from that corresponding position in a sequence from within the same clade. Most preferred are homologs or consensus sequences from Figures [16A-16G] 16A-16M. The internal sequences are preferably found virus sequences in the group of HIV-1 clades consisting of clades A, B, C, D, E, F, G and F/B.--

**Replacement for the first full paragraph on page 80, lines 7-33:**

--The amino acids in the separating sequence retain **abcdefg** assignment positions of the intervening sequence, wherein preferably the amino acids in positions **a** and **d** in the separating sequence are identical to their corresponding intervening sequence amino acids. In addition, in preferred embodiments, the amino acids in the separating sequence position **g** and **e** also are identical to their corresponding intervening sequence amino acids. Less preferably, an amino acid at any one of positions **a**, **d**, **g**, or **e** is conservatively substituted in the separating sequence (with a sequence other than that represented in the clade at that position). Most preferably, the amino acids in the separating sequence retain **abcdefg** assignment positions of the intervening sequence and an amino acid at any one of positions **a**, **d**, **g**, or **e** is substituted in the separating sequence with a corresponding amino acid from its homolog sequence from another HIV strain, from a consensus sequence of its homolog sequences from any one HIV clade, or from an amino acid substituted variant thereof. The amino acids in the separating sequence positions **b**, **c**, or **f**

can be any non-helix-breaking amino acid, with the preferences given in Figures 22 and [23A and B] 23A to 23D. Chimeras can be formed where an amino acid at any one of positions **a, d, g,** or **e** of the internal sequence of six amino acids is substituted in the helical peptide with an amino acid from the corresponding position of a different HIV virus strain. Likewise substitutions of the same nature can be made in flanking or in separating sequences. Preferred are compounds wherein the internal amino acid sequence is from any one of the peptide sequences from [Figure [23A and B] Figures 23A to 23D. More preferably, the compound of the invention is selected from the group consisting of constrained helical peptides of each possible sequence having any one or any combination of amino acid substitutions indicated in the constrained helical peptides series I to XII as shown in Figures [23A and 23B] 23A to 23D. In other embodiments, the compound is selected from the group consisting of constrained helical peptides of each possible sequence having any one or any combination of amino acid truncations indicated in the constrained helical peptide series I to XII as shown in Figures [23A and 23B] 23A to 23D. In yet other embodiments, the compound is selected from the group consisting of constrained helical peptides of each possible sequence having any one or any combination of amino acid substitutions indicated in the constrained helical peptide series I to XII as shown in Figures [23A and 23B] 23A to 23D in combination with any one or any combination of amino acid truncations indicated in the constrained helical peptide series I to XII as shown in Figures [23A and 23B] 23A to 23D. The "X" in these sequences can be any non helix-breaking amino acid.--